Advertisement: TTP Killer 50
2 July, 2018 - 15:26 By News Desk


Deploying a powerful and proprietary platform to discover and develop novel immuno-oncology therapeutics called Alphamers for solid tumours and leukaemias. 

Avvinity is jointly managed by Horizon Discovery Group, via its Research Biotech business, and Centauri Therapeutics Limited

Avvinity is a capital-efficient virtual company deploying up to £5.3million of initial funding and contracting its member companies to perform work on Avvinity’s behalf. The company plans to develop Alphamer drug candidates against a number of targets of unmet therapeutic need and then raise additional funds to take them into clinical trials.

Newsletter Subscription

Stay informed of the latest news and features